Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2019

01-05-2019 | Colorectal Cancer

Promising Long-Term Outcomes After Pelvic Exenteration

Authors: Yakup Kulu, MD, Arianeb Mehrabi, MD, Elias Khajeh, MD, Johannes Klose, MD, Johanna Greenwood, MD, Thilo Hackert, MD, Markus W. Büchler, MD, Alexis Ulrich, MD

Published in: Annals of Surgical Oncology | Issue 5/2019

Login to get access

Abstract

Background

Pelvic exenteration (PE) is a complex and challenging surgical procedure. The reported results of this procedure for primary and recurrent disease are limited and conflicting.

Methods

This study analyzed patient outcomes after all PEs performed in the authors’ department between October 2001 and December 2016. Relevant patient data were obtained from a prospective database. Morbidity and mortality were reported for all patients. For patients with malignant disease, differences in perioperative outcomes, prognostic indicators for overall survival, and local and systemic disease recurrence were analyzed using uni- and multivariate analyses.

Results

The study enrolled 187 patients. Of the 183 patients with malignant disease, 63 (38.2%) had primary locally advanced tumors and 115 (62.5%) had recurrent tumors. The 10-year overall survival rate was 63.5% for the patients with primary tumors that were curatively resected and 20.9% for the patients with recurrent disease (p = 0.02). The 10-year survival rate for the patients with extrapelvic disease who underwent curative resection was 37%. Multivariable analysis identified margin positivity (p < 0.01), surgery lasting longer than 7 h (p = 0.02), and recurrent disease (p < 0.01) as predictors of poor survival. Multivariate analysis of local and systemic disease recurrence showed recurrent disease (p < 0.01) as the only significant prognostic factor.

Conclusions

Pelvic exenteration has good long-term results, even for patients with extrapelvic disease. The oncologic outcome for patients with recurrent disease is worse than for patients with primary disease. However, even for these patients, long-time survival is possible.
Appendix
Available only for authorised users
Literature
1.
Brown KGM, Solomon MJ, Koh CE. Pelvic exenteration surgery: the evolution of radical surgical techniques for advanced and recurrent pelvic malignancy. Dis Colon Rectum. 2017;60:745–54.CrossRefPubMed
2.
Pawlik TM, Skibber JM, Rodriguez-Bigas MA. Pelvic exenteration for advanced pelvic malignancies. Ann Surg Oncol. 2006;13: 612–23.CrossRefPubMed
3.
4.
PelvEx Collaborative. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. Br J Surg. 2018;105(6):650–7.CrossRef
5.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral
6.
Gannon CJ, Zager JS, Chang GJ, et al. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol. 2007;14:1870–7.CrossRefPubMed
7.
Koh CE, Solomon MJ, Brown KG, et al. The evolution of pelvic exenteration practice at a single center: lessons learned from over 500 cases. Dis Colon Rectum. 2017;60:627–35.CrossRefPubMed
8.
Yang TX, Morris DL, Chua TC. Pelvic exenteration for rectal cancer: a systematic review. Dis Colon Rectum. 2013;56:519–31.CrossRefPubMed
9.
Bhangu A, Ali SM, Brown G, et al. Indications and outcome of pelvic exenteration for locally advanced primary and recurrent rectal cancer. Ann Surg. 2014; 259: 315–322.CrossRefPubMed
10.
Nielsen MB, Rasmussen PC, Lindegaard JC, et al. A 10-year experience of total pelvic exenteration for primary advanced and locally recurrent rectal cancer based on a prospective database. Colorectal Dis. 2012;14:1076–83.CrossRefPubMed
11.
Warren OJ, Solomon MJ. R0 resection, not surgical technique, is the key consideration in pelvic exenteration surgery. Tech Coloproctol. 2015;19:117–8.CrossRefPubMed
12.
13.
Rottoli M, Vallicelli C, Boschi L, et al. Outcomes of pelvic exenteration for recurrent and primary locally advanced rectal cancer. Int J Surg. 2017;48:69–73.CrossRefPubMed
14.
Vermaas M, Ferenschild FT, Verhoef C, et al. Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer. Eur J Surg Oncol. 2007;33:452–8.CrossRefPubMed
15.
Kusters M, Austin KK, Solomon MJ, et al. Survival after pelvic exenteration for T4 rectal cancer. Br J Surg. 2015;102:125–31.CrossRefPubMed
16.
Radwan RW, Jones HG, Rawat N, et al. Determinants of survival following pelvic exenteration for primary rectal cancer. Br J Surg. 2015;102:1278–84.CrossRefPubMed
17.
Speicher PJ, Turley RS, Sloane JL, et al. Pelvic exenteration for the treatment of locally advanced colorectal and bladder malignancies in the modern era. J Gastrointest Surg. 2014;18:782–8.CrossRefPubMed
Metadata
Title
Promising Long-Term Outcomes After Pelvic Exenteration
Authors
Yakup Kulu, MD
Arianeb Mehrabi, MD
Elias Khajeh, MD
Johannes Klose, MD
Johanna Greenwood, MD
Thilo Hackert, MD
Markus W. Büchler, MD
Alexis Ulrich, MD
Publication date
01-05-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-07090-0

Other articles of this Issue 5/2019

Annals of Surgical Oncology 5/2019 Go to the issue

Urologic Oncology

Long-Term Outcomes Following Partial Versus Complete Cystectomy in Advanced Colorectal Cancer with Regarding to the Extent of Bladder Invasion

Gastrointestinal Oncology

Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy

Sarcoma

Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04)

Colorectal Cancer

Survival Outcomes and Patterns of Management for Anal Adenocarcinoma

Peritoneal Surface Malignancy

Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei

Translational Research and Biomarkers

Cellular Senescence, Represented by Expression of Caveolin-1, in Cancer-Associated Fibroblasts Promotes Tumor Invasion in Pancreatic Cancer